GlassScriptPhysician profile
Tabita Morris
NPI 1740593003
$10,652.09
in general payments reported to CMS, 2019-2025
32 companies · $867 in 2025
The $867 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,122 · 2021: $1,797 · 2022: $1,592 · 2023: $2,100 · 2024: $1,890 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,476.68 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Janssen Pharmaceuticals, INC | $1,270.49 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,107.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $878.43 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $798.06 | 2019-2025 | |
| Gilead Sciences, INC. | $750.88 | 2021-2024 | Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $675.81 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $465.12 | 2019-2025 | Dificid, Zerbaxa, Verquvo |
| Paratek Pharmaceuticals, INC. | $341.32 | 2019-2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $302.57 | 2019-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.66 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $291.38 | 2022-2025 | Givlaari |
| Boston Scientific Corporation | $276.67 | 2019-2024 | Watchman Flx, Watchman Access System |
| Electromed, INC. | $276.26 | 2019-2024 | Smartvest |
| Allergan, INC. | $264.67 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $183.74 | 2021-2022 | |
| Melinta Therapeutics, LLC | $179.77 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Astrazeneca Pharmaceuticals LP | $171.88 | 2020-2025 | Wainua, Lokelma |
| Novo Nordisk INC | $121.16 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $102.49 | 2019-2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $91.62 | 2019 | |
| Bioxcel Therapeutics, INC. | $52.44 | 2023 | Igalmi |
| Sunovion Pharmaceuticals INC. | $49.39 | 2019 | |
| Insmed, INC. | $45.02 | 2022 | |
| Scpharmaceuticals INC. | $30.03 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.02 | 2020-2021 | |
| Inari Medical, INC. | $28.06 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cmp Pharma, INC. | $23.16 | 2021 | |
| Abbott Laboratories | $22.20 | 2024 | Freestyle Libre 3 |
| Kestra Medical Technology Services, INC. | $18.99 | 2024 | Assure Wcd |
| Shire North American Group INC | $15.99 | 2019 | |
| Tactile Systems Technology INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabita Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.